BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1984826)

  • 1. Etoposide in the management of metastatic breast cancer.
    Sledge GW
    Cancer; 1991 Jan; 67(1 Suppl):266-70. PubMed ID: 1984826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of etoposide in treatment of breast cancer.
    Nichols CR
    Semin Oncol; 1992 Dec; 19(6 Suppl 13):67-71. PubMed ID: 1492229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up).
    Icli F; Akbulut H; Onur H; Yalcin B; Demirkazık A; Senler FÇ
    Breast; 2011 Apr; 20(2):155-7. PubMed ID: 20951586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etoposide in gastric cancer.
    Macdonald JS; Havlin KA
    Semin Oncol; 1992 Dec; 19(6 Suppl 13):59-62. PubMed ID: 1492227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin Plus Ifosfamide with/without Etoposide as Salvage Treatment in Heavily-pre-treated Patients with Metastatic Breast Cancer.
    Habbel P; Kurreck A; Schulz CO; Regierer AC; Kaul D; Scholz CW; Neumann C; Possinger K; Eucker J
    Anticancer Res; 2015 Sep; 35(9):5091-5. PubMed ID: 26254412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.
    Slevin ML; Clark PI; Joel SP; Malik S; Osborne RJ; Gregory WM; Lowe DG; Reznek RH; Wrigley PF
    J Clin Oncol; 1989 Sep; 7(9):1333-40. PubMed ID: 2549204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 21-day oral etoposide for metastatic breast cancer: a phase II study and review of the literature.
    Saphner T; Weller EA; Tormey DC; Pandya KJ; Falkson CI; Stewart J; Robert NJ
    Am J Clin Oncol; 2000 Jun; 23(3):258-62. PubMed ID: 10857889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer.
    Wallerstein R; Spitzer G; Dunphy F; Huan S; Hortobagyi G; Yau J; Buzdar A; Holmes F; Theriault R; Ewer M
    J Clin Oncol; 1990 Nov; 8(11):1782-8. PubMed ID: 2121909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel in combination chemotherapy for metastatic breast cancer.
    Khayat D; Antoine E
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vincristine with high-dose etoposide in advanced breast cancer: a phase II trial of the Piedmont Oncology Association.
    Thomas GW; Muss HB; Jackson DV; McCulloch J; Ramseur W; McFarland J; Hoen H; Pavy M; Heath R
    Cancer Chemother Pharmacol; 1994; 35(2):165-8. PubMed ID: 7987995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoposide therapy for testicular cancer.
    Loehrer PJ
    Cancer; 1991 Jan; 67(1 Suppl):220-4. PubMed ID: 1984823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series.
    Giannone G; Milani A; Ghisoni E; Genta S; Mittica G; Montemurro F; Valabrega G
    Breast; 2018 Apr; 38():160-164. PubMed ID: 29413403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
    Cocconi G; Tonato M; Di Costanzo F; Bisagni G; Belsanti V; Buzzi F; Ceci G
    Eur J Cancer Clin Oncol; 1986 Jul; 22(7):761-4. PubMed ID: 3770033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
    Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ
    Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin in the management of breast cancer.
    Sledge GW; Roth BJ
    Semin Oncol; 1989 Aug; 16(4 Suppl 6):110-5. PubMed ID: 2669132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel (Taxotere) in combination: a step forward.
    Burris HA; Fields S; Peacock N
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
    Souhami RL; Spiro SG; Rudd RM; Ruiz de Elvira MC; James LE; Gower NH; Lamont A; Harper PG
    J Natl Cancer Inst; 1997 Apr; 89(8):577-80. PubMed ID: 9106647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etoposide in the management of non-small cell lung cancer.
    Ruckdeschel JC
    Cancer; 1991 Jan; 67(1 Suppl):250-3. PubMed ID: 1845848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced inoperable stomach cancer: a pilot study with the combination etoposide, adriamycin and cisplatin.
    Preusser P; Wilke H; Achterrath W; Neuhaus B; Balleisen L; Meyer J; Van de Loo J
    Anticancer Res; 1986; 6(5):1195-6. PubMed ID: 3800325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.